Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai welcomes initiation of new NICE Alzheimer’s guidance

Eisai welcomes initiation of new NICE Alzheimer’s guidance

28th March 2011

Eisai has welcomed the initiation of new guidance from the UK's National Institute for Health and Clinical Excellence (NICE) that will expand access to one of its Alzheimer's disease drugs.

A ruling from the healthcare regulator has come into effect on March 23rd 2011 that reverses a previous restriction on access to Alzheimer's medication to those with moderate to severe symptoms only.

As of this month, patients in England and Wales can be prescribed with drugs such as Eisai's Aricept when demonstrating mild forms of the condition, a decision that has been hailed as a "milestone" by Eisai.

The drug manufacturer states that by allowing early-stage patients to receive treatment, Alzheimer's sufferers will be able to remain independent and mentally unimpaired for longer.

"In compliance with the new guidance, Eisai will continue to make further contributions to address the diversified needs of and increase the benefits provided to patients and their families," it added.

Earlier this month, Eisai was granted approval from the European Commission to launch its drug Halaven as a treatment for breast cancer in the UK and Europe.ADNFCR-8000103-ID-800477581-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.